Trials / Terminated
TerminatedNCT00179738
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
A Multicenter, Single-Arm, Open-Label, Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®) In Subjects With Androgen Independent Prostate Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Celgene Corporation · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Subjects who qualify will receive single agent oral lenalidomide daily on days 1-21 every 28 day cycle. Subjects will continue on study until documented disease progression
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC5013 |
Timeline
- Start date
- 2005-04-01
- Completion
- 2007-04-01
- First posted
- 2005-09-16
- Last updated
- 2005-11-23
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00179738. Inclusion in this directory is not an endorsement.